
Utilizing Subcutaneous and IV Treatment for Improved Outcomes with Multiple Myeloma Patients
While significant advances have been made overall in the treatment of multiple myeloma, the management of transplant-ineligible patients remains challenging. Patients with multiple myeloma are not cured with conventional therapy. Treatment does, however, alleviate symptoms, improve quality of life, and prolong survival. The current standard of care for multiple myeloma patients includes an anti-CD38 monoclonal antibody in either first- or second-line treatment of myeloma. CANCER BUZZ spoke to Cindy Varga, MD, Hematologist at Atrium Health's Levine Cancer Institute in Charlotte, NC. Listen as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.